Correction: Mol Cancer 13, 8 (2014)

https://doi.org/10.1186/1476-4598-13-8

Following publication of the original article [1], an error was identified in the images presented in Fig. 4, specifically:

MiR-34a functioned as a tumor suppressor in MIBC cells. A The effect of ectopic miR-34a expression on MIBC cell proliferation was investigated by CCK-8. The miR-34a activity was mediated by transfection with miR-34a mimics or inhibitor respectively. Data are plotted as the mean ± SEM of 3 independent experiments relative to mock treatments. The effect of ectopic miR-34a expression on MIBC cell tumorgenesis was investigated by B) colony-formation and C) sphere-formation assay. Quantitative analyses of D) colony and E) sphere numbers (mean + SEM; n = 3; *p < 0.05). F Relative miR-34a expression in xenografts; G) Photographs of tumors excised 38 days after inoculation of stably transfected cells into nude mice; Mean xenograft tumor volume H) and weight I) in nude mice groups after indicated treatment (mean + SEM; n = 3; *p < 0.05)

Full size image

Figure 4B: incorrect images were originally used for Lenti-NC in 5637 cell line; the correct images are now used

Furthermore, two of the primer sequences listed in the Table S1 (part of ‘Additional file 3: Supplementary materials and methods’) contained typographical errors. The sequences for HGF F and GAPDH F have been corrected in the new version of the file.

The authors provided the journal with the original data files. The corrected version of Fig. 4 is provided here. The correction does not have any effect on the results or conclusions of the paper.

1. Li H, Yu G, Shi R, et al. Cisplatin-induced epigenetic activation of miR-34a sensitizes bladder cancer cells to chemotherapy. Mol Cancer. 2014;13:8. https://doi.org/10.1186/1476-4598-13-8.

   CAS Article PubMed PubMed Central Google Scholar

Download references

1. Heng Li and Gan Yu contributed equally to this work.

Authors and Affiliations

1. Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China

   Heng Li, Gan Yu, Runlin Shi, Ding Xia, Haibing Xiao, Xiaolin Guo, Wei Guan, Zhangqun Ye & Hua Xu

2. Translational Medicin Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China

   Wei Xiao

3. School of Health Sciences, Macao Polytechnic Institute, Macao, China

   Bin Lang

4. Department of Urology, First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China

   Xianguo Chen

1. Heng LiView author publications

   You can also search for this author in PubMed Google Scholar

2. Gan YuView author publications

   You can also search for this author in PubMed Google Scholar

3. Runlin ShiView author publications

   You can also search for this author in PubMed Google Scholar

4. Bin LangView author publications

   You can also search for this author in PubMed Google Scholar

5. Xianguo ChenView author publications

   You can also search for this author in PubMed Google Scholar

6. Ding XiaView author publications

   You can also search for this author in PubMed Google Scholar

7. Haibing XiaoView author publications

   You can also search for this author in PubMed Google Scholar

8. Xiaolin GuoView author publications

   You can also search for this author in PubMed Google Scholar

9. Wei GuanView author publications

   You can also search for this author in PubMed Google Scholar

10. Zhangqun YeView author publications

    You can also search for this author in PubMed Google Scholar

11. Wei XiaoView author publications

    You can also search for this author in PubMed Google Scholar

12. Hua XuView author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Wei Xiao or Hua Xu.

Additional file 3: Table S1

. Primer sets sequences used for qPCR in this study. Figure S1. CpG sites in the promoter region of miR-34a (n=14), and sequences of the primers used for amplification of converted DNA for sequenom massarray analysis. Figure S2. Expression of some well-known targets of miR-34a in 5637, T24 and HT-1376 cells following cisplatin treatment. mRNA expression of indicated genes were detected by qPCR.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

Cite this article

Li, H., Yu, G., Shi, R. et al. Correction: Cisplatin-induced epigenetic activation of miR-34a sensitizes bladder cancer cells to chemotherapy. Mol Cancer 21, 155 (2022). https://doi.org/10.1186/s12943-022-01614-9

Download citation

• Published: 28 July 2022

• DOI: https://doi.org/10.1186/s12943-022-01614-9

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative